Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases
Purpose
This phase III trial compares the effect of adding radiation therapy to usual care on the occurrence of bone-related complications in cancer patients with high-risk bone metastases that are not causing symptoms (asymptomatic). High-risk bone metastases are defined by their location (including hip, shoulder, long bones, and certain levels of the spine), or size (2 cm or larger). These bone metastases appear to be at higher risk of complications such as fracture, spinal cord compression, and/or pain warranting surgery or radiation treatment. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. The total dose of radiation can be delivered in a single day or divided in smaller doses for up to 5 days of total treatment. Usual care for asymptomatic bone metastases may include drugs that prevent bone loss, in addition to the treatment for the primary cancer or observation (which means no treatment until symptoms appear). Evidence has shown that preventative radiation therapy may be effective in lowering the number of bone metastases-related complications, however, it is not known if this approach is superior to usual care. Adding radiation therapy to usual care may be more effective in preventing bone-related complications than usual care alone in cancer patients with asymptomatic high-risk bone metastases.
Conditions
- Metastatic Malignant Neoplasm in the Bone
- Metastatic Malignant Solid Neoplasm
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- • Patients with polymetastatic cancer defined as more than 5 sites of radiographically-evident systemic metastatic disease (excluding intracranial disease) - "High-risk" asymptomatic bone metastasis (Brief Pain Inventory [BPI] score of < 5 on the "maximum" pain item) defined as fulfilling at least one of the following four high-risk criteria: - Bulky site of disease in bone ( ≥ 2 cm); - Disease involving the hip (acetabulum, femoral head, femoral neck), shoulder (acromion, glenoid, humeral head), or sacroiliac joints; - Disease in long bones occupying up to 2/3 of the cortical thickness (humerus, radius, ulna, clavicle, femur, tibia, fibula, metacarpals, phalanges); and/or - Disease in junctional spine (C7-T1, T12-L1, L5-S1) and/or disease with posterolateral element (pedicles and/or facet joints) involvement - NOTE: Sternum, rib, and scapula are defined as flat bones so lesions in these locations would only be included if bulky - Patients with any solid tumor type (excluding multiple myeloma) - Patients must have systemic disease evaluation through standard of care diagnostic imaging, including either CT chest/abdomen/pelvis or body positron emission tomography (PET)/CT, with radiology report available - Patients with treated brain metastases and no known leptomeningeal disease are eligible if these lesions have been treated prior to enrollment - Age ≥ 18 - Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2 or Karnofsky performance status (KPS) ≥ 60 - No previous radiotherapy to the intended enrolled sites of disease - No epidural spinal cord compression (ESCC) ≥ grade 1c (defined as deformation of the thecal sac with spinal cord abutment) at the enrolled bone metastasis(es) - No prior fracture at the enrolled bone metastasis(es)
Exclusion Criteria
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Prevention
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Active Comparator Arm I (standard of care) |
Patients continue to receive SOC systemic anti-cancer therapy or observation and bone modifying agents as determined by the treating physician. Additionally, patients optional blood sample collection on study. |
|
Experimental Arm II (RT, SOC) |
Patients continue SOC as in Arm I. Patients also undergo conventional RT or SBRT QD for up to 5 days (5 fractions) in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI and optional blood sample collection on study. |
|
Recruiting Locations
Fairbanks, Alaska 99701
Phoenix, Arizona 85004
Antioch, California 94531
Arroyo Grande, California 93420
Auburn, California 95602
Auburn, California 95603
Bakersfield, California 93301
Site Public Contact
661-323-4673
Berkeley, California 94704
Burlingame, California 94010
Cameron Park, California 95682
Carmichael, California 95608
Carmichael, California 95608
Castro Valley, California 94546
Dublin, California 94568
Site Public Contact
877-642-4691
Elk Grove, California 95758
Fremont, California 94538
Fresno, California 93720
Irvine, California 92612
Martinez, California 94553-3156
Site Public Contact
925-957-5400
Modesto, California 95355
Modesto, California 95356
Mountain View, California 94040
Oakland, California 94611
Orange, California 92868
Palo Alto, California 94301
Rancho Cordova, California 95670
Redwood City, California 94063
Site Public Contact
877-642-4691
Richmond, California 94801
Rocklin, California 95765
Rohnert Park, California 94928
Roseville, California 95661
Roseville, California 95661
Sacramento, California 95814
Sacramento, California 95816
Sacramento, California 95816
Sacramento, California 95823
Sacramento, California 95823
San Francisco, California 94115
San Leandro, California 94577
San Luis Obispo, California 93401
San Mateo, California 94401
San Rafael, California 94903
Santa Barbara, California 93105
Santa Clara, California 95051
Santa Cruz, California 95065
Santa Maria, California 93444
Santa Rosa, California 95403
South San Francisco, California 94080
Stockton, California 95204
Site Public Contact
209-461-5257
Stockton, California 95210
Sunnyvale, California 94086
Vacaville, California 95688
Vallejo, California 94589
Vallejo, California 94589
Walnut Creek, California 94596
Walnut Creek, California 94598
Woodland, California 95695
Aurora, Colorado 80012
Boulder, Colorado 80304
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80923
Denver, Colorado 80218
Englewood, Colorado 80113
Lakewood, Colorado 80228
Littleton, Colorado 80120
Longmont, Colorado 80501
Pueblo, Colorado 81004
Thornton, Colorado 80260
Westminster, Colorado 80023
Lewes, Delaware 19958
Millville, Delaware 19967
Newark, Delaware 19713
Newark, Delaware 19713
Newark, Delaware 19718
Rehoboth Beach, Delaware 19971
Wilmington, Delaware 19801
Honolulu, Hawaii 96819
Coeur d'Alene, Idaho 83814
Post Falls, Idaho 83854
Bloomington, Illinois 61701
Bloomington, Illinois 61704
Canton, Illinois 61520
Carbondale, Illinois 62902
Carterville, Illinois 62918
Carthage, Illinois 62321
Centralia, Illinois 62801
Chicago, Illinois 60611
Decatur, Illinois 62526
Decatur, Illinois 62526
DeKalb, Illinois 60115
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Effingham, Illinois 62401
Eureka, Illinois 61530
Galesburg, Illinois 61401
Geneva, Illinois 60134
Kewanee, Illinois 61443
Macomb, Illinois 61455
O'Fallon, Illinois 62269
O'Fallon, Illinois 62269
Oak Brook, Illinois 60523
Orland Park, Illinois 60462
Ottawa, Illinois 61350
Pekin, Illinois 61554
Pekin, Illinois 61554
Peoria, Illinois 61615
Peoria, Illinois 61615
Peoria, Illinois 61636
Peoria, Illinois 61637
Peru, Illinois 61354
Peru, Illinois 61354
Site Public Contact
815-664-4141
Princeton, Illinois 61356
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Warrenville, Illinois 60555
Washington, Illinois 61571
Goshen, Indiana 46526
Richmond, Indiana 47374
Ames, Iowa 50010
Site Public Contact
515-956-4132
Ames, Iowa 50010
Ankeny, Iowa 50023
Site Public Contact
515-241-3305
Cedar Rapids, Iowa 52402
Clive, Iowa 50325
Clive, Iowa 50325
Site Public Contact
515-241-3305
Creston, Iowa 50801
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Waukee, Iowa 50263
Site Public Contact
515-241-3305
West Des Moines, Iowa 50266
Lexington, Kentucky 40504
Lexington, Kentucky 40504
Lexington, Kentucky 40509
Louisville, Kentucky 40202
Louisville, Kentucky 40207
Site Public Contact
502-629-3465
Louisville, Kentucky 40217
Site Public Contact
502-629-3465
Louisville, Kentucky 40241
Bath, Maine 04530
Damariscotta, Maine 04543
Portland, Maine 04102
Sanford, Maine 04073
Site Public Contact
207-459-1600
Scarborough, Maine 04074
South Portland, Maine 04106
Baltimore, Maryland 21201
Baltimore, Maryland 21201
Site Public Contact
800-888-8823
Baltimore, Maryland 21215
Bel Air, Maryland 21014
Site Public Contact
443-643-3010
Columbia, Maryland 21044
Site Public Contact
443-546-1300
Easton, Maryland 21601
Glen Burnie, Maryland 21061
Site Public Contact
410-553-8100
Westminster, Maryland 21157
Site Public Contact
410-871-6400
Brainerd, Minnesota 56401
Burnsville, Minnesota 55337
Coon Rapids, Minnesota 55433
Deer River, Minnesota 56636
Detroit Lakes, Minnesota 56501
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Edina, Minnesota 55435
Fosston, Minnesota 56542
Hibbing, Minnesota 55746
Site Public Contact
218-786-3308
Maple Grove, Minnesota 55369
Maplewood, Minnesota 55109
Maplewood, Minnesota 55109
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55415
Monticello, Minnesota 55362
Park Rapids, Minnesota 56470
Robbinsdale, Minnesota 55422
Saint Cloud, Minnesota 56303
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Sandstone, Minnesota 55072
Shakopee, Minnesota 55379
Stillwater, Minnesota 55082
Virginia, Minnesota 55792
Waconia, Minnesota 55387
Willmar, Minnesota 56201
Woodbury, Minnesota 55125
Cape Girardeau, Missouri 63703
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Great Falls, Montana 59405
Havre, Montana 59501
Kalispell, Montana 59901
Missoula, Montana 59804
Kearney, Nebraska 68847
Omaha, Nebraska 68124
Omaha, Nebraska 68130
Omaha, Nebraska 68131
Lebanon, New Hampshire 03756
Bronx, New York 10461
Bronx, New York 10467
Clemmons, North Carolina 27012
Site Public Contact
888-716-9259
Statesville, North Carolina 28677
Site Public Contact
704-872-3630
Wilkesboro, North Carolina 28659
Site Public Contact
888-716-9253
Winston-Salem, North Carolina 27157
Site Public Contact
336-713-6771
Fargo, North Dakota 58103
Jamestown, North Dakota 58401
Beavercreek, Ohio 45431
Centerville, Ohio 45459
Cincinnati, Ohio 45219
Cincinnati, Ohio 45220
Cincinnati, Ohio 45242
Dayton, Ohio 45415
Findlay, Ohio 45840
Findlay, Ohio 45840
Findlay, Ohio 45840
Franklin, Ohio 45005
Greenville, Ohio 45331
Greenville, Ohio 45331
Kettering, Ohio 45409
Kettering, Ohio 45429
Troy, Ohio 45373
West Chester, Ohio 45069
Youngstown, Ohio 44501
Portland, Oregon 97227
Chadds Ford, Pennsylvania 19317
Chambersburg, Pennsylvania 17201
Ephrata, Pennsylvania 17522
Site Public Contact
717-721-4840
Erie, Pennsylvania 16505
Farrell, Pennsylvania 16121
Gettysburg, Pennsylvania 17325
Site Public Contact
877-441-7957
Greensburg, Pennsylvania 15601
Site Public Contact
724-838-1900
Hershey, Pennsylvania 17033-0850
Indiana, Pennsylvania 15701
Johnstown, Pennsylvania 15901
Site Public Contact
814-534-4724
Lebanon, Pennsylvania 17042
Meadowbrook, Pennsylvania 19046
Site Public Contact
215-938-3555
Mechanicsburg, Pennsylvania 17050
Monroeville, Pennsylvania 15146
Pittsburgh, Pennsylvania 15213
Site Public Contact
412-647-2811
Pittsburgh, Pennsylvania 15215
Site Public Contact
412-784-4900
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-621-2334
Pittsburgh, Pennsylvania 15243
Site Public Contact
412-502-3920
York, Pennsylvania 17403
Site Public Contact
877-441-7957
York, Pennsylvania 17403
Site Public Contact
877-441-7957
Saint Johnsbury, Vermont 05819
Mechanicsville, Virginia 23116
Midlothian, Virginia 23114
Richmond, Virginia 23226
Richmond, Virginia 23230
Silverdale, Washington 98383
Bridgeport, West Virginia 26330
Morgantown, West Virginia 26506
Parkersburg, West Virginia 26101
Princeton, West Virginia 24740
Site Public Contact
304-487-7515
Wheeling, West Virginia 26003
Site Public Contact
304-243-6442
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
Hayward, Wisconsin 54843
Madison, Wisconsin 53705
Site Public Contact
608-256-1901
Milwaukee, Wisconsin 53295
Site Public Contact
888-469-6614
Mukwonago, Wisconsin 53149
New Richmond, Wisconsin 54017
Oconomowoc, Wisconsin 53066
Site Public Contact
262-928-7878
Sheboygan, Wisconsin 53081
Spooner, Wisconsin 54801
Sturgeon Bay, Wisconsin 54235-1495
Superior, Wisconsin 54880
Site Public Contact
701-364-6272
Waukesha, Wisconsin 53188
More Details
- NCT ID
- NCT06745024
- Status
- Recruiting
- Sponsor
- NRG Oncology
Detailed Description
PRIMARY OBJECTIVE: I. To determine whether prophylactic radiation therapy (RT) to high-risk asymptomatic bone metastases decreases the occurrence of skeletal-related events (SREs), including pathologic fracture, spinal cord compression, and surgery to bone (not including palliative radiation for pain only), compared to standard of care (SOC). SECONDARY OBJECTIVES: I. To compare overall survival (OS) between study arms. II. To compare occurrence of any SREs (including RT for palliation of pain) among enrolled bone metastasis(es) between study arms. III. To compare occurrence of hospitalizations related to any SREs in enrolled bone metastasis(es) between study arms. IV. To compare pain-related quality of life (QOL) between study arms. V. To characterize adverse events of RT and compare to SOC. EXPLORATORY OBJECTIVES: I. To evaluate overall QOL, functional status, and quality-adjusted life years between study arms. II. To evaluate any hospitalizations (from any cause) between study arms. III. To characterize differences in primary and secondary endpoints between study arms (a) among the represented racial and ethnic groups (e.g. Black, White, Hispanic/Latino, Asian/Pacific Islander, and Native American) and (b) by sex. IV. To evaluate the heterogeneity of radiation treatment effect based on cancer-related factors (histology, criteria indicating high-risk for SRE), treatment-related factors (bone modifying agent use, radiation dose/ technique), and patient demographic factors (age, sex, race/ethnicity, and health-related social needs). OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients continue to receive SOC systemic anti-cancer therapy or observation and bone modifying agents as determined by the treating physician. Additionally, patients undergo optional blood sample collection on study. ARM II: Patients continue SOC as in Arm I. Patients also undergo conventional RT or stereotactic body radiation therapy (SBRT) once daily (QD) for up to 5 days (5 fractions) in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo computed tomography (CT) or magnetic resonance imaging (MRI) and optional blood sample collection on study. After completion of study treatment, patients are followed up at 3, 6, 12 and 24 months.